Skip to main content

Evidence

Where the evidence stands

Retrospective feasibility demonstrated on a US adult clinical cohort. Retrospective external testing on an independent US cohort is complete; the result is company-reported, unpublished and not yet peer reviewed.

No performance figures appear on this site until a public preprint or peer-reviewed paper is available. When one is, it will be linked here.

Inputs & Population

What the model reads, and who it is for

Inputs

Values already present in a routine adult workup — standard blood work, vitals and basic history, drawn and recorded as part of ordinary care.

Intended population

The primary workflow is designed for adults (18+) on a routine adult panel. It is not designed for pediatric use. Confirmatory kidney testing follows a flag; every clinical decision remains the provider's.

Patent-pending technology. Provisional patent filed March 2026.

Study Ledger

Every claim carries the stage it has actually reached

Demonstrated, complete but unpublished, in progress, designed, or still a hypothesis. Each entry sits at the stage it has actually reached.

  • 1Demonstrated
  • 1Complete, unpublished
  • 1In progress
  • 2Study designed
  • 1Research hypothesis

  1. Demonstrated

    Retrospective feasibility

    Demonstrated

    Feasibility demonstrated retrospectively on a US adult clinical cohort: the model produces risk stratification from routine-panel inputs. Retrospective results do not guarantee prospective clinical performance.

  2. Complete, unpublished

    Retrospective external testing

    Complete, unpublished

    The product model was tested retrospectively, without retraining, on an independent US cohort, and the analysis is complete. The result is company-reported and not yet peer reviewed. Site-specific generalizability and prospective clinical impact remain to be tested.

  3. In progress

    Peer-reviewed publication

    In progress

    The manuscript reporting the external test is in preparation. Performance figures will appear here once a preprint or paper is public; none are stated before then.

  4. Study designed

    Biopharma: first sponsor retrospective study

    Study designed

    A governed, model-to-data retrospective study design: whether model-assisted review of routine panels would surface candidates for confirmatory kidney evaluation that a standard site query misses, and at what review cost. Written as design; no results exist to report.

    Biopharma: progression validation design

    Study designed

    A validation study design for CKD progression questions — serial routine panels read as a longitudinal trajectory. A separate model and a separate evidence path from the prevalence work; it would need its own validation before any claim is made.

  5. Research hypothesis

    Prospective clinical evaluation

    Research hypothesis

    Prospective evaluation in live clinical workflows, measuring whether a flag leads to completed confirmatory testing, is the next stage. Its design will be published alongside the pilots that carry it.

Primary Sources

Clinical and methodological references

The clinical claims this site makes trace to primary literature and guidelines.

Discuss the evidence program
For health systems